Results overview: Found 1 records in 0.04 seconds.
Articles, 1 records found
Articles 1 records found  
1.
9 p, 525.7 KB Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 / Spinner, Christoph D. (Technical University of Munich) ; Felizarta, Franco (Office of Franco Felizarta) ; Rizzardini, Giuliano (University of the Witwatersrand) ; Philibert, Patrick (Hôpital Europen de Marseille) ; Mitha, Essack (Newtown Clinical Research) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Stephan, Christoph J. (Universitätsklinikum Frankfurt) ; Degrosky, Michelle (ViiV Healthcare) ; Bainbridge, Veronica (GlaxoSmithKline) ; Zhan, Joyce (GlaxoSmithKline) ; Dumitrescu, Teodora Pene (GlaxoSmithKline) ; Jeffrey, Jerry L. (ViiV Healthcare. Research Triangle Park) ; Xu, Jianfeng (GlaxoSmithKline) ; Halliday, Fiona (GlaxoSmithKline) ; Gan, Jianjun (GlaxoSmithKline) ; Johnson, Mark (ViiV Healthcare. Research Triangle Park) ; Gartland, Martin (ViiV Healthcare. Research Triangle Park) ; Joshi, Samit R. (ViiV Healthcare) ; Lataillade, Max (ViiV Healthcare) ; Universitat Autònoma de Barcelona
GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily therapy. This phase IIa double-blind (sponsor-unblinded), randomized, placebo-controlled, adaptive study evaluated antiviral effect, safety, tolerability, and PK of once-daily GSK'254 monotherapy administered with food (moderate-fat meal) in HIV-1-positive, treatment-naive adults. [...]
2022 - 10.1093/cid/ciab1065
Clinical Infectious Diseases, Vol. 75 Núm. 5 (january 2022) , p. 786-794  

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.